Inhibition of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives

Medicinal Chemistry

Volumn 5, Issue 5, 2009, Pages 398-410

  Tatyana, Kharlamova ^a   Francesca, Esposito ^b   Luca, Zinzula ^b   Giovanni, Floris ^b   Yung Chi, Cheng ^c   Ginger, E Dutschman ^c   Enzo, Tramontano ^b  

^a Institute of Chemical Sciences Academy of Sciences of Kazakhstan   (Kazakhstan)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthraquinones; Drug discovery; Enzyme inhibition; HIV 1; Reverse transcriptase; Ribonuclease H; RNase H; RT

Indexed keywords

7 BROM 6 O PHENACYL 1,8 DIHYDROXY 3 METHYLANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; EMODIN; NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG DNA BINDING; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

BASE SEQUENCE; BINDING SITES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG INTERACTIONS; EMODIN; ENZYME INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; KINETICS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H;

EID: 70349153876     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609789117840     Document Type: Article

References (37)

1. Arts, E.J.; Le Grice, S.F.J. Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Progr. Nucl. Acid Res. Mol. Biol., 1998, 58, 341-393.
2. Hughes, S.H.; Arnold, E.; Hostomsky Z. RNase H of Retroviral Reverse Transcriptases, in Ribonucleases H. Crouch, R.J.; Toulmé J.J., Ed.: Les Editions INSERM: Paris, France, 1998, pp.195-224.
3. Klarmann, G.J.; Hawkins, M.E.; Le Grice, S.T.J. Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target. AIDS Rev., 2002, 4, 183-194.
4. Tisdale, M.; Schulze, T.; Larder, B.A.; Moelling, K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J. Gen. Virol., 1991, 72, 59-66.
5. Tramontano, E. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini-Rev. Med. Chem., 2006, 6, 727-737.
6. Shaw-Reid, C.A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, S.; Olsen, D.; Carroll, S.; Embrey, E.; Wai, J.; Miller, M.; Cole, J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem., 2003, 278, 2777-2780.
7. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1 H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res., 2005, 65, 117-124.
8. Klumpp, K.; Mirzadegan, T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Des., 2006, 12, 1909-1922.
9. Borkow, G.; Fletcher, R. S.; Barnard, J.; Arion, D.; Motakis, D.; Dmitrienko, G. I.; Parniak, M. A. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4- tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry, 1997, 36, 3179-3185.
10. Himmel, D.M.; Sarafianos, S.G.; Dharmasena, S.; Hossain, M.M.; McCoy-Simandle, K.; Ilina, T.; Clark, Jr. A.D.; Knight, J.L.; Julias, J.G.; Clark, P.K.; Krogh-Jespersen, K.; Levy, R.M.; Hughes, S.H.; Parniak, M.A.; Arnold, E. HIV-1 Reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol., 2006, 1, 702-712.
11. Singh, R.; Geetanjali; Chauhan, S.M.S. 9,10-Anthraquinones and Other Biologically Active Compounds from the Genus. Rubia. Chem. Biodivers., 2004, 1, 1241-1264.
12. Huang, Q.; Lu, G.; Shen, H.M.; Chung, M.C.; Onq, C.N. Anti-cancer properties of anthraquinones from Rhubarb. Med. Res. Rev., 2007, 27, 609-630.
13. Srinivas, G.; Babykutty, S.; Sathiadevan, P.P.; Srinivas P. Molecular mechanism of emodin effect: transition from laxative ingredient to antitumor agent. Med. Res. Rev., 2007, 27, 591-608.
14. Yim, H.; Lee, Y.H.; Lee, C.H.; Lee S.K. Emodine, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med., 1999, 65, 9-13.
15. Koyama, M.; Takahashi, K.; Chou, T.C.; Darzynkiewicz, Z.; Kapuscinski, J.; Kelly, T.R.; Watanabe, K.A. Intercalating agents with covalent bond forming capability. A novel type of potential anti-cancer agents. 2. Derivatives of chrysophanol and emodine J. Med. Chem., 1989, 32, 1594-1599.
16. Muller, S.O.; Lutz, W.K.; Sopper, H. Factors affecting the genotoxic potency ranking of natural anthraquinones in mammalian cell culture systems. Mut. Res., 1998, 414, 125-129.
17. Tan, J.H.; Zhang, Q.X.; Huang, Z.S.; Chen, Y.; Wang, X.D.; Gu, L.Q.; Wu, J.Y. Synthesis, DNA binding and cytotoxicity of new pyrazole emodin derivatives. Eur. J. Med. Chem., 2006, 41, 1041-1047.
18. Barnard, D.L.; Huffman, J.H.; Morris, J.L.B.; Wood, S.G.; Hughes, B.G.; Sidwell, R.W. Evaluation of antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cyromegalovirus. Antiviral Res., 1992, 17, 63-77.
19. Shuangsuo, D.; Zhengguo, Z.; Yunru, C.; Xin, Z.; Baofeng, W.; Lichao, Y.; Yan'an, C. Inhibition of the replication of hepatitis B virus in vitro by emodine. Med. Sci. Monit., 2006, 12, 302-306.
20. Koyama, J.; Inoue, M.; Morita, I.; Kobayashi, N.; Osakai, T.; Nishino, H.; Tokuda, H. Correlation between reduction potentials and inhibitory effects on Epstein-Barr virus activation by emodine derivatives. Cancer Lett., 2006, 241, 263-267.
21. Farnet, C.M.; Wang, B.; Lipford, J.R.; Bushman, F.D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. USA, 1996, 93, 9742-9747.
22. Deng, J.; Sanchez, T.; Neamati, N.; Briggs, J.M. Dynamic pharmacopore model optimization: identification of novel HIV-1 integrase inhibitors. J. Med. Chem., 2006, 49, 1684-1692.
23. Starnes, M.C.; Cheng, Y-C. Human immunodeficiency virus reverse transcriptase-associated RNase H activity. J. Biol. Chem., 1989, 264, 7073-7077.
24. Tramontano E.; Cheng, Y-C. HIV-1 reverse transcriptase inhibition by dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharmacol., 1992, 43, 1371-1376.
25. Yonetani, T. The Yonetani-Theorell graphical method for examining overlapping subsite of enzyme centers. Methods Enzymol., 1982, 87, 500-509.
26. Elion, G.B.; Singer, S.; Hitchings, G.H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem., 1954, 208, 477-488.
27. Dezinot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. J. Immunol. Methods, 1986, 89, 271-277.
28. Mellors, J.W.; Dutschman G.E.; Im G.-J.; Tramontano E.; Winkler S.R.; Cheng Y-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol., 1992, 41, 446-451.
29. Larder, B. A.; Chesebro, B.; Richman, D.D. Susceptibilities of zidovudine -susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother., 1990, 34, 436-441.
30. Rice, P.; Craigie, R.; Davies, D.R. Retroviral integrases and their cousins. Curr. Opin. Struct. Biol., 1996, 6, 76-83.
31. Rice, P.A.; Baker, T.A. Comparative architecture of transposase and integrase complexes. Nat. Struct. Biol., 2001, 8, 302-307.
32. Hang, Q.L.; Li, Y.; Yang, Y.; Cammack, N.; Mirzadegan, T.; Klumpp, K. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Comm., 2007, 352, 341-350.
33. Shaw-Reid, C.A.; Feuston, B.; Munshi, V.; Getty, K.; Jrueger, J.; Hazuda, D.J.; Parniak, M.A.; Miller, M.D.; Lewis, D. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry, 2005, 44, 1595-1606.
34. Gopalakrishnan, V.; Benkovic, S. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc. Natl. Acad. Sci. USA, 1992, 89, 10763-10767.
35. Palaniappan, C.; Fay, P.J.; Bambara, R.A. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem., 1995, 270, 4861-4869.
36. Mohan, P.; Loya, S.; Avidan, O.; Verma, S.; Dhindsa, G.S.; Wong, M.F.; Huang, P.P.; Yashiro, M.; Baba, M.; Hizi, A. Synthesis of naphthalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. J. Med. Chem., 1994, 37, 2513-2519.
37. Min, B-S.; Miyashiro, H.; Hattori, M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother. Res., 2002, 16, S57-S62.